NIH Record-01_11_2000--Varmus Leaves NIH with Vision for Enhancing ...
Varmus Leaves NIH with Vision for Enhancing New York Biotech. By Rich McManus. ( First of two parts). A week before he left the directorship of NIH to take ...
http://nihrecord.od.nih.gov/newsletters/01_11_2000/story03.h...
|
BioPortfolio - Biocorporate Search
YORKbiotech is a Regional Innovation Network at the centre of the Greater Toronto Area. The mission of YORKbiotech is to act as a catalyst, harnessing the
...
http://www.bioportfolio.com/biocorporate/BioCorporate_Direct...
|
Archive article : Naturejobs
10 Aug 2005 ... Published on 1 September 2005. Investment in New York biotech infrastructure and basic research could draw more entrepreneurs to the area ...
http://www.nature.com/naturejobs/archive/prospects/0501.html...
|
:CNY Biotechnology Research Center
"...the future of New York's biotech sector is bright. The federal government projects that biotech and pharmaceutical companies will hire 12.5 percent more
...
http://www.upstate.edu/biocenter/...
|
drug discovery@nature.com
... $5 million in the third quarter of 2001 and a projected $9 million in the fourth quarter, according to SG Cowen (New York) biotech analyst Phil Nadeau.
...
http://www.nature.com/drugdisc/news/articles/nbt0203-115.htm...
|
Keck Graduate Institute
He is an active member of the New York Biotech Association, The Biotechnology Industry Organization (BIO), the Public Relations Society of America, ...
http://www.kgi.edu/x6089.xml...
|
Nature jobs newsletter
A boost for the Big Apple 1 September 2005 Investment in New York biotech infrastructure and basic research could draw more entrepreneurs to the are. ...
http://www.nature.com/naturejobs/etoc/etoc_sep2005.html...
|
BioWorld Today
Scanning through BioWorld Today, Rupert noted a write-up on Odessa's talk at the New York Biotech Association. It seemed she was on a suicidal bent. ...
http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher...
|
Actemra poised to launch IL-6 inhibitors : Article : Nature ...
With partner Sanofi-aventis, the New York biotech is exploring ways to treat the long list of disorders in which IL-6 is a known culprit. ...
http://www.nature.com/nbt/journal/v26/n9/full/nbt0908-957.ht...
|
RIT - University News
... dean of the College of Science at RIT, and Gary Skuse, director of bioinformatics at RIT, surveyed the workforce needs of the New York biotech
industry. ...
http://www.rit.edu/news/?r=44513...
|
